1. Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line
   Ladan Teimoori-Toolabi et al, 2015, Anti-Cancer Drugs CrossRef
2. Glucagon-like peptide 2 in colon carcinogenesis: Possible target for anti-cancer therapy?
   Vinicius Kannen et al, 2013, Pharmacology & Therapeutics CrossRef
3. Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
   Shaorong Yu et al, 2013, PLoS ONE CrossRef